Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer

RON (recepteur d'origine nantais) and MET (hepatocyte growth factor receptor) are tyrosine kinase receptors. Various cancers have aberrant RON and MET expression and activation, which contribute to cancer cell proliferation, invasiveness, and metastasis. Here, we explored RON and MET expression...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Chen-Yu, Xu, Xiang-Ming, Hong, Bo, Wu, Zhi-Gang, Qian, Yun, Weng, Tian-Hao, Liu, Yi-Zhi, Tang, Tao-Ming, Wang, Ming-Hai, Yao, Hang-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906148/
https://www.ncbi.nlm.nih.gov/pubmed/31867280
http://dx.doi.org/10.3389/fonc.2019.01377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906148/
https://www.ncbi.nlm.nih.gov/pubmed/31867280
http://dx.doi.org/10.3389/fonc.2019.01377

Ejemplares similares